Alkermes Plc - Company Profile
Powered by 
All the data and insights you need on Alkermes Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Alkermes Plc Strategy Report
- Understand Alkermes Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development, and commercialization of drugs for the treatment of cancer, neurodegenerative and central nervous system (CNS) diseases. The company’s proprietary products include Aristada and Aristada Initio an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It grants licenses under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors and pharmacies. The company has global operations. Alkermes is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
Connaught Hse, 1 Burlington Road, Dublin, 00000
Website
www.alkermes.com
Telephone
353 1 7728000
No of Employees
2,100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALKS (NASD)
Revenue (2022)
$1.7B
49.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
324.8%
(2022 vs 2021)
Market Cap*
$4.1B
Net Profit Margin (2022)
XYZ
250.2%
(2022 vs 2021)
* As of and is in US$
Alkermes Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed Products | Alkermes |
| Aristada – Schizophrenia | Aristada |
| Aristada Initio - Schizophrenia | Vivitrol |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company signed an agreement with Novo Nordisk to sell its development and manufacturing facility in Athlone, Ireland. |
| 2023 | Contracts/Agreements | In May, the company signed an agreement with Davis Marcus Partners to build a new, 220,000-square-foot laboratory and office facility. |
| 2022 | Plans/Strategy | In November, the company announced its plans to separate oncology business. |
Competitor Comparison
| Key Parameters | Alkermes Plc | AbbVie Inc | Sanofi | Novartis AG | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | Ireland | United States of America | France | Switzerland | United States of America |
| City | Dublin | North Chicago | Paris | Basel | Princeton |
| State/Province | - | Illinois | Ile-de-France | - | New Jersey |
| No. of Employees | 2,100 | 50,000 | 87,994 | 76,057 | 34,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard F. Pops | Chief Executive Officer; Chairman | Executive Board | 2011 | 61 |
| Iain M. Brown | Senior Vice President; Chief Financial Officer | Senior Management | 2021 | 54 |
| Blair C. Jackson | Chief Operating Officer; Executive Vice President | Senior Management | 2021 | 50 |
| Thomas Harvey | Senior Vice President - Information Technology; Chief Information Officer | Senior Management | - | - |
| David J. Gaffin | Chief Compliance Officer; Executive Vice President; Chief Legal Officer; Secretary | Senior Management | 2018 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward